Team

Meet Our Team of Experts

We are a collaborative and solutions-focused team with diverse skills, perspectives, and ideas.

Ribometrix team conversing

Our Leadership

The Ribometrix management team has decades of drug development, RNA biology, and company-building experience. Our leaders are responsible for directing the company’s science, strategy, and operations, as well as supporting and developing Ribometrix employees.

Jonathan Kearns, B.B.A.

VP, Finance & Operations

James Lanter, Ph.D.

Head of Discovery

William S. Marshall, Ph.D.

Chairman of the Board

William S. Marshall, Ph.D., is an independent life sciences consultant to various biopharma companies, investors, foundations and academic institutions. Prior to that he was the President, Chief Executive Officer, Co-Founder, and Director of miRagen Therapeutics, Inc. (NASDAQ: MGEN). miRagen discovered and developed a series on microRNA modulators, three of which demonstrated clinical proof of concept in the areas of hematological malignancy, fibrosis, and induction of neo-angiogenesis. miRagen merged with Viridian Therapeutics in 2020. Prior to founding miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in biochemistry from the University of Wisconsin-Madison and his Ph.D. in chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.

Katie Warner, Ph.D.

President, CSO & Founder

Katie co-founded Ribometrix with Kevin Weeks and was an early pioneer in SHAPE technologies, showing in 2009 with Dave Mathews and Kevin Weeks that SHAPE data can be used to model RNA secondary structure with high accuracy.

Katie continued her work with Adrian Ferré-D’Amaré and Chris Abell to show the first structure-based proof-of-principle that RNA is targetable by fragments. She has solved multiple RNA-small molecule crystal structures, including the fluorogenic RNAs “Spinach” and “Corn.”

Katie received a B.A. in chemistry from the University of North Carolina at Chapel Hill, and an M.Phil. in pathology and Ph.D. in chemistry from the University of Cambridge. Katie was a Beckman Scholar, a Churchill Scholar, an RNA Society/Scaringe awardee and an NIH-Oxford-Cambridge Scholar.

Chris Echeverri, Ph.D.

Head of R&D Alliances & Strategy

Chris is an independent life sciences consultant assisting young biopharma companies with top-level strategic, R&D and operational support, drawing on over 25 years of industry experience including 15 leading a 45-staff preclinical CRO that made pioneering contributions to the field of RNAi-based screening.

Since joining Ribometrix as a senior consultant in October 2017, Chris has applied his unusually diverse skill sets to help drive a broad range of company activities. After initially building up and running core operational processes including contracts, records, due diligence and IT management, his focus of recent years has turned primarily to R&D alliance management and corporate strategy. Alongside his work for Ribometrix, Chris was also a co-founder and senior consultant to Caraway Therapeutics, providing operational support including contracts, records and due diligence management from its 2017 seed stage until the company’s acquisition by Merck in November 2023.

Prior to his consulting work, Chris was the founding CEO/CSO of Cenix BioScience, a biotechnology company with operations in Germany and Belgium, where he built up and led groundbreaking RNAi-driven R&D capabilities, successfully commercialized over 15 years through contract research and technology development programs. In addition to developing the first commercially available genome-wide siRNA libraries (licensed and marketed by Ambion, now Thermo), his teams completed >100 studies combining high throughput siRNA screening with high content, multi-parametric microscopy-based assays to advance preclinical programs across many indications for a wide range of large pharma and biotechs.

Chris received his B.Sc. and M.Sc. in biology from the University of Ottawa, Canada. He earned his Ph.D. in molecular cell biology at the University of Massachusetts, and completed postdoctoral work in cell biology and functional genomics at the European Molecular Biology Laboratory in Heidelberg, Germany.

1 / 3
“RNA is the central conduit of information in every cell, if you target RNA biology, you can target almost anything. Ribometrix has the tools and the team to make this happen.”
Kevin Weeks, Founder and Scientific Advisor
Ribometrix

Board of Directors

William S. Marshall, Ph.D.

Chairman of the Board

William S. Marshall, Ph.D., is an independent life sciences consultant to various biopharma companies, investors, foundations and academic institutions. Prior to that he was the President, Chief Executive Officer, Co-Founder, and Director of miRagen Therapeutics, Inc. (NASDAQ: MGEN). miRagen discovered and developed a series on microRNA modulators, three of which demonstrated clinical proof of concept in the areas of hematological malignancy, fibrosis, and induction of neo-angiogenesis. miRagen merged with Viridian Therapeutics in 2020. Prior to founding miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in biochemistry from the University of Wisconsin-Madison and his Ph.D. in chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.

Hakan Goker, Ph.D.

Hakan Goker, Ph.D.

Hakan Goker, Ph.D., is Managing Director of M Ventures and heads the biotechnology investments covering healthcare and life sciences. Hakan joined M Ventures in 2013 and has been investing in the sector for 15 years. Previously, Hakan was a partner at Aescap Venture investing in European opportunities. Hakan started his investment career at Atlas Venture where he was part of the investment team in London focusing on global investment opportunities in healthcare and medical technologies across the U.S., Europe, and Asia.

He was instrumental in the creation and financing, business, and R&D strategies of multiple companies in their formation years including Orphazyme, Bicycle, Nimbus Discovery, and f-Star while at Aescap and Atlas. Hakan continues his active investing role and represents M Ventures on multiple portfolio companies. He comes from an academic background receiving his Ph.D. in oncology from the Institute of Cancer Research/ University of London, UK and continuing his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London. Hakan is based in Amsterdam at the M Ventures head office.

Kseniya Simpson, Ph.D.

Kseniya Simpson is a Principal at Hatteras Venture Partners, an early-stage, healthcare-focused venture capital firm, where she focuses on investing in innovative biotech companies. She has more than 10 years of experience working with life sciences companies of all stages. Prior to Hatteras, Kseniya was with Triangle Insights Group, where she worked as a Strategy Consultant, advising biotech and pharma companies on a wide variety of topics including company and asset diligence, pipeline strategy, clinical development, and commercial preparedness. Kseniya is a scientist by training and has conducted research in the areas of RNA therapeutics, nucleic acid delivery, lipid monolayers, and tissue engineering. She has also worked at Yale Ventures and served as a teaching fellow and lecturer at Yale.

Kseniya earned a Ph.D. in Cellular and Molecular Physiology from Yale University where she worked on siRNA therapeutics under the mentorship of W. Mark Saltzman, Ph.D. and received the Ruth L. Kirschstein National Research Service Award. She holds B.S. degrees in Chemistry and Biological Chemistry from the University of Chicago.

1 / 3